- Home
- SYRS
as 02-21-2025 4:00pm EST
Syros Pharmaceuticals Inc is a biopharmaceutical company committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies.
| Founded: | 2011 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 5.7M | IPO Year: | 2016 |
| Target Price: | $3.00 | AVG Volume (30 days): | 1.2M |
| Analyst Decision: | Hold | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.16 - $7.96 | Next Earning Date: | 03-26-2025 |
| Revenue: | $386,000 | Revenue Growth: | -95.61% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Syros Pharmaceuticals Inc. (SYRS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Simonian Nancy A | SYRS | Director | Dec 2 '24 | Sell | $0.27 | 37,070 | $10,016.31 | 4,000 | |
| Simonian Nancy A | SYRS | Director | Nov 25 '24 | Sell | $0.27 | 134,713 | $35,739.36 | 4,000 |
Latest Syros Pharmaceuticals Inc. News
SYRS Breaking Stock News: Dive into SYRS Ticker-Specific Updates for Smart Investing
Reuters
5 days ago
'We are back' Greek shipyards say after decades of pain
Just Auto
a month ago
Kia starts series production of Syros in India
Just Food
2 months ago
South Africa’s Westfalia Fruit acquires Belgian avocado products maker Syros
Just Auto
2 months ago
Kia launches Syros compact SUV in India
Zacks
3 months ago
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal
TipRanks
3 months ago
Syros Pharmaceuticals downgraded to Neutral from Buy at H.C. Wainwright
Clinical Trials Arena
3 months ago
Syros stock craters after lead cancer therapy flops in Phase III trial
Business Wire
3 months ago
Syros Announces Topline Data from SELECT-MDS-1 Phase 3 Trial of Tamibarotene in Higher-Risk Myelodysplastic Syndrome with RARA Gene Overexpression
Compare SYRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SYRS Syros Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.